Study finds diabetes drug dapagliflozin may benefit patients with heart failure

Patients with heart failure and preserved ejection fraction (HFpEF) often have a heavier burden of symptoms and functional limitations, and their quality of life is also poor; by targeting abnormalities in cardiac metabolism, sodium-glucose cotransporter 2 (SGLT2) ) Inhibitors may be able to improve these barriers

The impact of dapagliflozin on selected secondary endpoints and supporting responder analysis

Image source: DOI:10.

Heart failure with preserved ejection fraction (HFpEF) often occurs when the lower left cavity of the heart cannot be normally congested.

Previous research results have shown that SGLT2 inhibitors may reduce the risk of death from cardiovascular disease and the risk of hospitalization in patients with HFpEF.

The researchers randomly assigned 324 HFpEF patients from the United States to receive dapagliflozin or placebo for 12 weeks, and used the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at the end of the trial.

The investigator found that compared with the placebo group, patients in the dapagliflozin treatment group reported overall improvement in symptoms, physical limitations, and exercise functions; and the adverse events between the two groups were also relatively similar

In summary, the results of this study show that the 12-week dapagliflozin therapy may significantly improve patients' self-reported symptoms, body restriction, and exercise function, and is well tolerated in patients with chronic HFpEF

Note: The original text has been deleted

Original source:

Nassif, ME, Windsor, SL, Borlaug, BA et al.